{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:44:04Z","timestamp":1782744244514,"version":"3.54.5"},"reference-count":30,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","award":["CMRPG3N1331"],"award-info":[{"award-number":["CMRPG3N1331"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The evidence from studies comparing 45 and 30 mg starting doses of first-line dacomitinib for advanced epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>This study aimed to compare the clinical efficacy and safety of two starting-dose first-line dacomitinib strategies in patients with advanced EGFR-mutated NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>This study employed a multicenter retrospective cohort design.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A total of 189 patients with stage IIIB\/IV EGFR-mutated NSCLC who received first-line dacomitinib between October 2020 and September 2023 at one of four Taiwanese centers were analyzed. Among them, 59 patients started with 45 mg and 130 patients started with 30 mg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The 45-mg group included significantly more male patients and had higher baseline body weight and body mass index. The objective response rate (ORR) and disease control rate were comparable between the 45-mg (72.9% and 94.9%) and 30-mg (66.9% and 91.5%) groups (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.623). The median progression-free survival was 18.53 months for patients treated with 45 mg dacomitinib and 18.03 months for patients treated with 30 mg dacomitinib (hazard ratio (HR), 0.958; 95% confidence interval (CI), 0.681\u20131.349;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.807). The median overall survival was 40.4 and 49.97 months, respectively (HR, 1.078; 95% CI, 0.640\u20131.815;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.778). However, patients receiving a starting dose of 45 mg dacomitinib experienced significantly higher rates of skin toxicity, paronychia, diarrhea, stomatitis, and anorexia and required dose reduction more frequently (all\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This study suggests that a 30-mg starting dose of dacomitinib may provide similar efficacy with improved tolerability compared with 45 mg. Prospective noninferiority studies are warranted to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359261458739","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T03:10:02Z","timestamp":1782443402000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics and outcomes of advanced EGFR-mutated NSCLC treated with 45 or 30 mg starting doses of dacomitinib: a retrospective multicenter analysis"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0173-7509","authenticated-orcid":false,"given":"Ping-Chih","family":"Hsu","sequence":"first","affiliation":[{"name":"Division of Thoracic Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan"},{"name":"Department of Medicine, College of Medicine, Chang Gung University, Taoyuan City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6415-2965","authenticated-orcid":false,"given":"How-Wen","family":"Ko","sequence":"additional","affiliation":[{"name":"Division of Thoracic Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan"},{"name":"Department of Medicine, College of Medicine, Chang Gung University, Taoyuan City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Chung","family":"Chiu","sequence":"additional","affiliation":[{"name":"Division of Thoracic Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan"},{"name":"Department of Medicine, College of Medicine, Chang Gung University, Taoyuan City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3755-0287","authenticated-orcid":false,"given":"Shih-Hong","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Thoracic Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Hao","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Medicine, New Taipei Municipal TuCheng Hospital, New Taipei City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Shu","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine, Chang Gung University, Taoyuan City, Taiwan"},{"name":"Department of Thoracic Medicine, New Taipei Municipal TuCheng Hospital, New Taipei City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ching","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine, Chang Gung University, Taoyuan City, Taiwan"},{"name":"Division of Thoracic Oncology, Department of Respiratory and Critical Care Medicine, Chang Gung Memorial Hospital, Chiayi Branch, Chiayi County, Taiwan"},{"name":"Department of Respiratory Care, Chang Gung University of Science and Technology, Chiayi Campus, Chiayi County, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3309-937X","authenticated-orcid":false,"given":"Scott Chih-Hsi","family":"Kuo","sequence":"additional","affiliation":[{"name":"Division of Thoracic Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan"},{"name":"Department of Medicine, College of Medicine, Chang Gung University, Taoyuan City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2285-2787","authenticated-orcid":false,"given":"Jia-Shiuan","family":"Ju","sequence":"additional","affiliation":[{"name":"Division of Thoracic Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Chou","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine, Chang Gung University, Taoyuan City, Taiwan"},{"name":"Division of Pulmonary and Critical Care Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Ta","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Medicine, Chang Gung Memorial Hospital, 123 Dinghu Road, Gueishen District, Taoyuan City 33378, Taiwan"},{"name":"Division of Thoracic Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan"},{"name":"Department of Internal Medicine, Taoyuan Chang Gung Memorial Hospital, Taoyuan City, Taiwan"},{"name":"Department of Respiratory Therapy, College of Medicine, Chang Gung University, Taoyuan City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040938"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2088"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810699"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70393-X"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv276"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.2806"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70604-1"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30608-3"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01441-6"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph16040534"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.02.025"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.08.1805"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-023-00991-5"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-019-01117-3"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.819674"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2025.14947"},{"key":"e_1_3_4_19_2","unstructured":"National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 3.0. Bethesda MD: National Cancer Institute https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf (2006 accessed 18 April 2026)."},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-81704-4"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2024.04.04"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw322"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S273866"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.70098"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14674"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/17534666221132731"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1249106"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411817"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf079"},{"issue":"2","key":"e_1_3_4_31_2","article-title":"Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study","volume":"76","author":"Duan JC","year":"2026","unstructured":"Duan JC, Zhong J, Sun BY, et al. Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study. CA Cancer J Clin 2026; 76(2): e70071.","journal-title":"CA Cancer J Clin"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261458739","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359261458739","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261458739","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:46:45Z","timestamp":1782740805000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359261458739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":30,"alternative-id":["10.1177\/17588359261458739"],"URL":"https:\/\/doi.org\/10.1177\/17588359261458739","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"17588359261458739"}}